<DOC>
	<DOC>NCT02192190</DOC>
	<brief_summary>The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.</brief_summary>
	<brief_title>A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology (ACR) criteria and confirmed with Xrays and ACR functional class of I to III Have been on stable dose of prescription Nonsteroidal AntiInflammatory Drugs (NSAIDS), celecoxib, tramadol, or acetaminophen of at least 2000 mg per day for at least 20 days in the past month Willing to stop all analgesics for OA pain during the study Experienced pain in the target knee as based on the Visual Analog Scale (VAS) Allergic to LY2951742, celecoxib, other NSAIDS, including aspirin, and similar drugs Arthritis of the knee from other causes Uncontrolled hypertension Have OA pain that requires treatment with potent opioids, systemic corticosteroids, intraarticular injections, duloxetine, or venlafaxine Moderate to severe renal impairment Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>